Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?
For over 40 years, percentage blood basophils has been used to estimate survival and to define the accelerated phase [1][2][3][4][5][6].Recently, this use has declined or disappeared, especially since the introduction of tyrosine kinase inhibitor (TKI) therapy.No widely used CML survival prediction model includes percentage blood basophils [7].Putting a nail in the coffin, the 2022 WHO classification of myeloid neoplasms, for good reason, eliminated accelerated phase CML making percentage blood basophils irrelevant [8].In contrast, the 2022 International Consensus Classification (ICC) retained accelerated phase CML.The 2025 European LeukemiaNet classification seems undecided [9, 10] (reviewed in refs.[11, 12]).It's interesting to consider how and why percentage blood basophils came into prominence in CML, and why percentage and not concentration was the unit of quantification, like haemoglobin (g/L) and WBCs (x10 9 /L).An explanation is that automated particle counters able to estimate basophil concentration became widely used beginning in the late 1980s.Previously, basophil quantity was assessed only by a visual blood cell differential estimate resulting in percentage.But now, if percentage blood basophils has gone the way of the Dodo bird, last sighted in 1662, might there be residual value were blood basophils to be quantified as a concentration?The units of how a quantity is expressed are quirky.Consider a shrewdness of apes, a congregation of alligators, a murder of crows, a mob of kangaroos, a parliament of owls, etc.So it is reasonable to ask: Why was the quantity of blood basophils previously expressed as a percentage, and is this quantification important??Today, four methods are widely used to quantify blood basophils: (1) visual differential analyses; (2) automated particle counting; (3) multi-parameter flow cytometry (MPFC); and (4) artificial intelligence (AI) and machine learning.Visual differential analyses of WBCs are the reference standard for basophil enumeration despite well-known limitations including non-uniform distribution, observer variability and statistical
Authors
- Eduard Cmunt (ORCID: https://orcid.org/0000-0001-6486-7402)
- Eva Kriegová (ORCID: https://orcid.org/0000-0002-8969-4197)
- Kristyna Kubikova
- Martin Radvanský (ORCID: https://orcid.org/0000-0002-8421-7658)
- Miloš Kudělka (ORCID: https://orcid.org/0000-0002-7219-1008)
- Lukáš Stejskal
- Michal Karas (ORCID: https://orcid.org/0000-0001-8824-1594)
- Petra Bělohlávková (ORCID: https://orcid.org/0000-0001-8728-7443)
- Sen Yang (ORCID: https://orcid.org/0000-0002-0402-6422)
- Jarmila Juráňová
- Xiao-Shuai Zhang
- Jiri Mayer
- Qian Jiang
- Hana Klamova
- Lucia Turcsanyi
- Edgar Faber
- Robert Peter Gale
- Megan Othus
Institutions
- VSB - Technical University of Ostrava (CZ)
- Peking University (CN)
- Charles University (CZ)
- Masaryk University (CZ)
- University Hospital Ostrava (CZ)
- Fred Hutch Cancer Center (US)
- Institute of Haematology and Blood Transfusion (CZ)
- University Hospital Brno (CZ)
- University Hospital Olomouc (CZ)
- Peking University People's Hospital (CN)
- University Hospital Hradec Králové (CZ)
- General University Hospital in Prague (CZ)
- Imperial College London (GB)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Leukemia
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1038/s41375-026-02910-9
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- National Natural Science Foundation of China